bioMerieux (OTCMKTS:BMXMF) Stock Rated “Reduce” by Wall Street Brokerages

bioMerieux (OTCMKTS:BMXMF) has earned a consensus recommendation of “Reduce” from the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a hold recommendation to the company.

A number of equities research analysts have recently weighed in on BMXMF shares. Piper Sandler began coverage on shares of bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday, September 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th.

bioMerieux Trading Down 0.4%

Shares of OTCMKTS BMXMF opened at $85.00 on Thursday. bioMerieux has a 1 year low of $77.00 and a 1 year high of $132.52. The company’s 50-day moving average is $83.39 and its 200 day moving average is $87.41.

bioMerieux Company Profile

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.